SOURCE: BioForce Nanosciences Holdings, Inc.

September 16, 2008 09:00 ET

BioForce Nanosciences Announces ViriChip Project Funding in Senate Appropriations Bill

AMES, IA--(Marketwire - September 16, 2008) - BioForce Nanosciences Holdings, Inc. (OTCBB: BFNH), a leader in systems integration at the micro and nano scales to create products for the life sciences, is pleased to announce that funding for its ViriChip™ pathogen detection system has been secured by Senator Tom Harkin (D-IA) in the Senate Fiscal Year 2009 Department of Defense Appropriations bill. Senator Harkin, a four term senator, is a senior member of the Senate Defense Appropriations Subcommittee. The bill must pass the Senate and the House, and receive the President's signature, before this funding is finalized.

BioForce's ViriChip platform is a patented ultramicro scale biosensor platform for detecting and identifying microbial pathogens, in particular viruses. This system could represent a breakthrough in medical virology and in other fields where virus detection is a fundamental necessity, including biodefense and environmental monitoring. The ViriChip platform employs BioForce's Nano eNabler™ system to create miniature arrays of multiple biological substances, such as antibodies, to which different pathogens will adhere.

ViriChip's advantages over conventional methods of pathogen detection are anticipated to include the number of different pathogens which can be detected in one test, the speed with which the testing can be performed, the ability to perform testing under environmental conditions where alternative testing methodologies are not viable, and portability of the system due to the miniaturized nature of the test. These advantages offer the potential to dramatically change the way in which the United States military monitors field environments for the presence of dangerous pathogens.

Kerry Frey, BioForce's President and Chief Executive Officer, said, "We are appreciative of Senator Harkin's support of this project. Importantly, the ViriChip platform has the potential to improve the safety of our military personnel, and ultimately save lives. ViriChip is but one example of our portfolio of scientific applications involving our platform technology, the ability to deposit micro to nano scale amounts of biological materials onto surfaces in a precise and flexible manner, which is embodied in our Nano eNabler system."

Senator Harkin's announcement of this funding can be found on his website at

For further information about this release please contact Greg Brown, Chief Financial Officer of BioForce at 515-233-8333 ext# 118, or Rich Kaiser, Investor Relations at 757-306-6090.

About BioForce Nanosciences Holdings, Inc.

BioForce Nanosciences creates products and solutions for the life sciences by integrating biological and mechanical systems at the micro and nano scales. BioForce's flagship product, the Nano eNabler molecular printer, gives the Company and its customers a platform for development and discovery by printing tiny domains of biological materials on surfaces with nanometer spatial precision. BioForce technology is being used in areas such as biosensor functionalization; pattering and cell adhesion; and the printing of proteins to guide neural cell growth. For more information, visit or call 515-233-8333.

This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.

Contact Information

  • Contacts:

    Company Contact
    Gregory D. Brown
    Chief Financial Officer
    515-233-8333 ext. 118
    Email Contact

    Investor Relations
    Yes International
    Rich Kaiser